PR1 Determinants of Orphan Drug Prices in France: Regression Analysis  by Korchagina, D et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A337
treatment line. Association between the annual treatment cost per patient and 
the attributes was studied using Pearson correlation coefficient (for quantitative 
variables), ANOVA (for qualitative variables), and generalized linear model using 
gamma distribution. Results: Annual treatment costs varied from 1,500€ to almost 
1,000,000€ . Bivariate analysis showed a significant association between the annual 
treatment cost and disease prevalence, age group, treatment line, alternative treat-
ments, therapeutic area, and ATC class (p< 0.05 for all). Significantly higher cost was 
observed in pediatric population, first treatment line, metabolic diseases, or in case 
of absence of alternative treatment. Multivariate analysis including these variables 
did not showed significant results. Given the complex correlation structure between 
the co-variates, the model including only the prevalence and alternative treatments 
was tested. Both co-variates were significant. ConClusions: Disease prevalence 
and unmet needs seems to be the main drivers of ODs prices while the level of 
clinical evidence and disease severity had no impact. However, this is difficult to 
justify statistically because of high variance and small number of observations. 
Interestingly, ASMR score presented by the HAS as main price driver was not shown 
having an impact on drug prices.
PR2
PRedicting Post-Amnog RebAte outcomes foR oncology dRugs
Subramanian D, Lazaro V
Qlaar Pte. Ltd., Singapore, Singapore
objeCtives: New drugs launching into Germany undergo benefit assessment 
by G-BA, followed by a price negotiation with GKV-Spitzenverband (GKV-SV). In 
this paper we analyze the determinants of German rebate outcomes for oncol-
ogy drugs. Methods: We used the (Coveragedecisions} payer decision database 
as the basis of this analysis. This database consists of systematically abstracted 
data from publicly available payer decisions on pricing, reimbursement, HTA 
and formulary coverage decisions from 21 countries worldwide, covering all new 
molecular entities (NMEs) approved in EU or US since 2011. We extracted data from 
the (Coveragedecisions} payer decision database on G-BA benefit assessment and 
GKV-SV pricing outcomes of all oncology NMEs with a known GKV-SV pricing out-
come. The data extracted included G-BA benefit rating at subgroup level, relative 
sizes of subgroups, intervention and comparator costs by subgroups, time limi-
tations on benefit determination and magnitude of rebate. We then conducted a 
stepwise multiple linear regression with backward elimination, with magnitude 
of post-AMNOG rebate as the dependent variable, and benefit category, difference 
between intervention and comparator costs and presence of time limit on benefit 
recommendation as the independent variables. Results: Of the 27 benefit assess-
ments analyzed, rebates varied from 10%-54%. The final model (adjusted R square 
0.75; F statistic 9.35; p< 0.001) showed that the difference between intervention 
and comparator costs was a significant predictor of rebate (p= 0.004). Compared to 
‘indication of considerable benefit’, ‘no benefit’ (p= 0.001) and ‘hint of minor benefit’ 
(p< 0.001) were associated with significantly higher rebates. Though other benefit 
ratings did not achieve statistical significance, directionally, ‘proof of minor benefit’ 
and ‘indication of lower benefit’ were associated with higher rebates compared to 
‘indication of considerable benefit’. ConClusions: Based on our analysis, GKV 
rebate for oncology drugs can be expressed using a multiple regression equation, 
as a function of G-BA benefit rating category and incremental cost vs. comparator.
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objeCtives: The growing costs of medicines have forced many countries to imple-
ment measures to lower the prices of originators and generics after patent expira-
tion. Measures taken in Austria include Generic Price Linkage System, where there 
are strict upper limits for the prices of generics and also for originators after the 
entry of generics. Measures taken in Finland include Generic Substitution and 
Reference Pricing, where competition plays an important role. The aim of this 
study is to compare the effects of the measures taken in Austria and in Finland on 
the prices of originators and generics. Methods: We included in the analysis ten 
active ingredients whose sales were high in Finland, which were reimbursable in 
both countries, and whose patent protection expired during the years 2010–2012. 
The analysis was based on time series, which covered 6 months before and 12 
months after the entry of the first generic. The changes in price levels were meas-
ured in terms of wholesale prices proportioned to the number of Defined Daily 
Doses in the package (EUR/DDD). Results: One year after generic entry, prices 
for originators had fallen, on average, by 46% in Austria and by 21% in Finland. 
Prices for generics were 66% lower in Austria and 59% lower in Finland than the 
prices of originators before generic entry. The mean number of generics per active 
ingredient was 6.3 in Austria and 5.1 in Finland. ConClusions: The pricing sys-
tem applied in Austria appears to be more efficient in lowering prices than the 
system used in Finland, which contradicts claims that free competition lowers 
generic prices more efficiently than linking them to the price of the originator. 
This finding may be due to the way the Finnish Reference Price System has been 
constructed.
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objeCtives: Recent advances in treating Hepatitis C (HCV) have prompted sig-
nificant debate about affordability. The objective of this research was to investi-
gate Health Technology Assessment (HTA) agencies’ approach to assessment and 
the impact of evidence criteria on recommendations. Methods: HTA reports 
published on HCV since 2014 were reviewed. The four most frequently assessed 
drugs were further scrutinized in terms of clinical benefit, costs and recommen-
understand the total cost of ownership as this will become ever more important for 
future market access, reimbursement and financial discussions.
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objeCtives: Given the high burden of cardiovascular diseases treated in primary 
prevention with the implantable cardioverter defibrillator (ICD), the monitor of 
healthcare expenditure related to such diseases is essential for health policy mak-
ers. This study assessed the variation in costs of patients with ICD over time, from 
3 years before the first implant up to 8 years after. Methods: Patients covered 
by Lombardy Healthcare System (HS) who underwent an ICD implantation in the 
period 2003-2010 were identified through regional healthcare administrative data-
bases (HAD). Data extracted from these HAD were linked with clinical information 
collected in the national ICD registry, and for each patient we selected the first 
implant performed in primary prevention. We identified drug prescriptions, hospi-
talizations and outpatient visits provided to patients for their cardiovascular disease 
during the 3 years before and the 8 years after the implant. For the same period, we 
estimated the trend in mean annual per capita cost through the Bang and Tsiatis 
method, that considers censoring in cost data. Results: Patients with a first ICD 
implanted in primary prevention were 6,936 (82% males, mean age 65 years) and 
we observed a yearly mortality rate of 6.9% (95% Confidence Interval (CI): 6.6-7.3) 
during follow-up. During the 3 years before the implant, the mean annual per capita 
cost was € 3,424 (95%CI: 3,331-3,537) and it increased to € 4,136 (95%CI: 4,004-4,262) 
after ICD implantation. However, before the ICD implantation we observed a grow-
ing trend in mean annual per capita costs, while after the intervention this trend 
was negative. ConClusions: Our study confirmed the high economic impact of 
cardiovascular diseases on the HS when treating subjects with left ventricular sys-
tolic dysfunctions or heart failure. Different trends in the healthcare expenditure 
were detected pre and post ICD implantation, but the significance of such difference 
should be further explored.
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objeCtives: 18F-FDG-PET/CT is accurate in detecting distant metastases (DM) 
in breast cancer patients scheduled for neoadjuvant chemotherapy. If DMs are 
screen-detected in an early phase, morbidity and mortality may be reduced. 
Because 18F-FDG-PET/CT comes at a significant cost, we compared its expected 
cost-effectiveness in stage II/III breast cancer patients of the UK, the US and the 
Netherlands (NL) vs. the gold-standard (X-thorax/liver sonography/bone scan (UK/
NL) and CT-thorax-abdomen/bone scan (US)). Methods: A time-dependent Markov 
model compared expected Life Year (LY) and cost/Quality-adjusted Life Year (QALY) 
gained in four breast cancer subtypes (ER-/HER2+;ER+/HER2+;ER-/HER2-;ER+/HER2-) 
over a 5-year time horizon from a hospital perspective. Sensitivity and specific-
ity of imaging and type of systemic and local treatments were derived from the 
Netherlands Cancer Institute. Epidemiological, survival and utility data were esti-
mated from literature or informed by expert assumptions. Costs (2013) were derived 
from national tariffs (UK and NL), and from the Centres for Medicaid and Medicare 
Services (US). Results: 18F-FDG-PET/CT is more sensitive (53% vs. 15%) and specific 
(97% vs. 94%) than the gold-standard. LYs and QALYs gained were similar across 
subtypes, ranging from 0.025 to 0.027 and 0.0037 to 0.0044 respectively. In all coun-
tries, ER+HER2+ was the least and ER+HER2- the most costly group. 18F-FDG-PET/
CT is expected to be cost-effective in the NL and the US (with highest ICERs of € 165/
QALY in ER+/HER2+ and $750 in ER-HER2+), with probabilities of cost-effectiveness 
ranging from 46-52% and 62-72% respectively, but not in the UK, with a 66-75% prob-
ability, depending on tumor subtype. ConClusions: Using 18F-FDG-PET/CT for DM 
screening in stage II/III breast cancer is expected to result in incremental QALY gains 
in all subtypes and countries. Due to costs differences between countries, 18F-FDG-
PET/CT is expected to be cost-effective in the US and the NL, but not in the UK.
PRicing studies
PR1
deteRminAnts of oRPhAn dRug PRices in fRAnce: RegRession AnAlysis
Korchagina D1, Vataire A2, Toumi M3, Falissard B4, Aballéa S2
1University of Paris-Sud, Paris, France, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, 
Marseille, France, 4Maison de Solenn, Paris, France
objeCtives: No specific market access process has been developed for orphan 
drugs (ODs) in France, but there is an unspoken will to support these medicines. 
Pricing process of ODs is unclear, and many of them became blockbusters despite 
the small size of the targeted population. The aim of the study is to identify the 
main drivers of ODs prices in France. Methods: ODs prices were extracted from 
Ameli database. Drugs and diseases attributes were defined based on the reports 
of the European Medicines Agency and Haut Authorité de Santé (HAS). Attributes 
included the prevalence, ATC class, therapeutic area, disease severity, alternative 
treatments, level of clinical evidence, SMR and ASMR scores, year assessment, and 
